Sequent Scientific Ltd - 512529 - Shareholding for the Period Ended June 30, 2021
Sequent Scientific Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here15-07-2021
15-07-2021
SEQUENT SCIENTIFIC LTD. - 512529 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Krunal ShahDesignation :- Company Secretary and Compliance Officer15-07-2021
Sequent Scientific up 9% on EUGMP nod for its tablets dosage form in Turkey
With over 120 product registrations, Sequent is the third-largest player in the Turkish ruminant market with a consolidated market share of around 10 per cent15-07-2021
SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dear Sir / Madam, We enclose herewith a copy of Press Release that is being issued by the Company, in connection with the above mentioned subject. You are requested to take the same on record.14-07-2021
SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the provision of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of advertisement published on July 02, 2021, in 'Financial Express' and 'Mumbai Lakshadeep' newspaper providing Extracts of Audited Financial Results of the Company for the quarter and year ended March 31, 2021. Kindly take the same on record.02-07-2021
Earnings Call for Q4FY21 of Sequent Scientific
Conference Call with Sequent Scientific Management and Analysts on Q1FY22 Performance and Outlook. Listen to the full earnings transcript.01-07-2021
Sequent Scientific Ltd - 512529 - Corporate Action-Board approves Dividend
The Board of Directors at their meeting held today have recommended a final dividend of Rs. 0.50 (25%) per equity share for the financial year ended March 31, 2021.30-06-2021
Sequent Scientific Ltd - 512529 - Outcome Of Board Meeting Held On June 30, 2021 Along With Audited Standalone & Consolidated Financial Results And Press Release For The Quarter And Year Ended March 31, 2021
Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2021. In this regard, kindly find enclosed the following30-06-2021
Sequent Scientific Ltd - 512529 - Outcome Of Board Meeting Held On June 30, 2021 Along With Audited Standalone & Consolidated Financial Results And Press Release For The Quarter And Year Ended March 31, 2021
Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2021.30-06-2021